Thursday 16 October, 2025
Objectives: Esmirtazepine is a novel agent under development for insomnia. This is a pooled population analysis of the PK of…
Read morePoster: Applications- CNS
Modeling the Dropout from Longitudinal Adverse Event Data: Selecting Optimal Titration Regimens
Thursday 16 October, 2025
Background: Dizziness and somnolence are the predominant adverse events (AEs) reported in the treatment of Generalized Anxiety Disorder (GAD) with…
Read moreSupporting the recommended paediatric dosing regimen for rufinamide using clinical trial simulation
Thursday 16 October, 2025
Background: Rufinamide marketing application was reviewed recently by the CHMP (Committee for medicinal products for human use), for the treatment…
Read moreUsing VT (total volume of distribution from PET) in estimating the PK-Receptor Occupancy relationship in the absence of reference regions.
Thursday 16 October, 2025
Introduction: In a PET (Positron Emission Tomography) study, receptor occupancy (RO) data can be obtained from the fractional decrease in the…
Read morePharmacokinetics of a single bolus of propofol in Chinese children of different ages
Thursday 16 October, 2025
PDF of posterObjectives: 1. To determine a complete pharmacokinetic profile of a single dose of propofol in different aged Chinese…
Read morePopulation pharmacokinetics of NS2330 and its major metabolite in Alzheimer’s disease patients
Thursday 16 October, 2025
Objectives & Background: NS2330 is a new central nervous system active drug under clinical development for Alzheimer’s disease and Parkinson’s…
Read moreEfficacy modelling of NS2330 in mild Alzheimer’s disease patients
Thursday 16 October, 2025
Objectives & Background: NS2330 is a new drug under clinical development for the treatment of Alzheimer’s disease (AD). A population…
Read morePK and PK/PD modeling of CB1 blocker antagonism of THC induced CNS and Heart Rate effect
Thursday 16 October, 2025
Objectives: The purpose of this study was to develop a pharmacokinetic / pharmacodynamic (PK/PD) model for the characterization of the…
Read morePopulation pharmacokinetic analysis of pramipexole extended-release formulation in Parkinson’s Disease (PD) patients
Thursday 16 October, 2025
Background and Objectives: A pramipexole extended release (ER) formulation administered once daily was developed to facilitate improved compliance compared to…
Read moreBlood-brain barrier transport helps explain discrepancies in in vivo potency between oxycodone and morphine
Thursday 16 October, 2025
Objectives: The objective of this study was to evaluate the brain pharmacokinetic-pharmacodynamic (PKPD) relationships of unbound oxycodone and morphine in…
Read more